ATROPINE JUNO atropine sulfate monohydrate 1.2mg/1mL injection BP ampoule

Χώρα: Αυστραλία

Γλώσσα: Αγγλικά

Πηγή: Department of Health (Therapeutic Goods Administration)

Αγόρασέ το τώρα

Δραστική ουσία:

atropine sulfate monohydrate, Quantity: 1.2 mg/mL

Διαθέσιμο από:

Juno Pharmaceuticals Pty Ltd

Φαρμακοτεχνική μορφή:

Injection, solution

Σύνθεση:

Excipient Ingredients: sodium chloride; water for injections; hydrochloric acid

Οδός χορήγησης:

Intramuscular, Intravenous, Subcutaneous

Μονάδες σε πακέτο:

1mL x 50

Τρόπος διάθεσης:

(S4) Prescription Only Medicine

Θεραπευτικές ενδείξεις:

INDICATIONS AS AT 30 SEPTEMBER 2003 : Surgery: Atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. The use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. After surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. Cardiopulmonary resuscitation: Atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. Anticholinesterase Poisoning: Atropine sulfate is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, Amanita muscaria mushrooms or other compounds with anticholinesterase activity. A cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Περίληψη προϊόντος:

Visual Identification: Clear, colourless, particle-free solution.; Container Type: Ampoule; Container Material: PE; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

Καθεστώς αδειοδότησης:

Registered

Ημερομηνία της άδειας:

2022-07-01

Αναζήτηση ειδοποιήσεων που σχετίζονται με αυτό το προϊόν